Does maternal MDR1 C1236T polymorphism have an effect on placental arsenic levels?

Environmental Toxicology and Pharmacology

Volumn 41, Issue , 2016, Pages 142-146

  Kaya Akyüzlü, Dilek ^a   Kayaalti, Zeliha ^a   Doğan, Derya ^a   Söylemezoğlu, Tülin ^a  

^a ANKARA UNIVERSITY   (Turkey)

Author keywords

Arsenic; Human multidrug resistance 1 (MDR1); MDR1 C1236T polymorphism; Phospho glycoprotein (P gp); Placental tissue

Indexed keywords

ARSENIC; GENOMIC DNA; MULTIDRUG RESISTANCE PROTEIN 1; ABCB1 PROTEIN, HUMAN; CYTOSINE; MULTIDRUG RESISTANCE PROTEIN; THYMINE;

ADULT; ARSENIC POISONING; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; FEMALE; FETOPLACENTAL UNIT; FETUS; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; HUMAN TISSUE; MALE; PLACENTAL TRANSFER; POLYMERASE CHAIN REACTION; PRENATAL EXPOSURE; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; TISSUE LEVEL; VENOUS BLOOD; CHEMISTRY; GENETICS; MATERNAL EXPOSURE; METABOLISM; PLACENTA; PREGNANCY; SINGLE NUCLEOTIDE POLYMORPHISM; YOUNG ADULT;

ADULT; ARSENIC; CYTOSINE; FEMALE; GENOTYPE; HUMANS; MATERNAL EXPOSURE; P-GLYCOPROTEINS; PLACENTA; POLYMORPHISM, SINGLE NUCLEOTIDE; PREGNANCY; THYMINE; YOUNG ADULT;

EID: 84949665949     PISSN: 13826689     EISSN: 18727077     Source Type: Journal    
DOI: 10.1016/j.etap.2015.11.019     Document Type: Article

References (19)

1. Bellusci C.P., Rocco C., Aulicino P., Mecikovsky D., Curras V., Hegoburu S., Bramuglia G.F., Bologna R., Sen L., Mangano A. Influence of MDR1 C1236T polymorphism on lopinavir plasma concentration and virological response in HIV-1-infected children. Gene 2013, 522(1):96-101.
2. Bosch T.M., Huitema A.D., Doodeman V.D., Jansen R., Witteveen E., Smit W.M., Jansen R.L., Van Herpen C.M., Soesan M., Beijnen J.H., Schellens J.H. Pharmacogenetic screening of CYP3A and ABCB1 in relation to population pharmacokinetics of docetaxel. Clin. Cancer Res. 2006, 12(19):5786-5793.
3. Camus M., Deloménie C., Didier N., Faye A., Gil S., Dauge M.C., Mabondzo A., Farinotti R. Increased expression of MDR1 mRNAs and P-glycoprotein in placentas from HIV-1 infected women. Placenta 2006, 27(6-7):699-706.
4. Ceckova-Novotna M., Pavek P., Staud F. P-glycoprotein in the placenta: expression, localization, regulation and function. Reprod. Toxicol. 2006, 22(3):400-410.
5. Dudarewicz M., Baranska M., Rychlik-Sych M., Trzcinski R., Skretkowicz J., Dziki A., Skretkowicz J. The importance of C1236T polymorphism in the ABCB1/MDR1 gene in assessment of susceptibility to inflammatory bowel diseases in the Polish population. Prz. Gastroenterol. 2013, 8(1):38-43.
6. Gil S., Saura R., Forestier F., Farinotti R. P-glycoprotein expression of the human placenta during pregnancy. Placenta 2005, 26(2-3):268-270.
7. Hemauer S.J., Nanovskaya T.N., Abdel-Rahman S.Z., Patrikeeva S.L., Hankins G.D., Ahmed M.S. Modulation of human placental P-glycoprotein expression and activity by MDR1 gene polymorphisms. Biochem. Pharmacol. 2010, 79(6):921-925.
8. Juliano R.L., Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Biophys. Acta 1976, 455(1):152-162.
9. Kimchi-Sarfaty C., Oh J.M., Kim I.W., Sauna Z.E., Calcagno A.M., Ambudkar S.V., Gottesman M.M. A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science 2007, 315(5811):525-528.
10. Leslie E.M. Arsenic-glutathione conjugate transport by the human multidrug resistance proteins (MRPs/ABCCs). J. Inorg. Biochem. 2012, 108:141-149.
11. Liu J., Liu Y., Powell D.A., Waalkes M.P., Klaassen C.D. Multidrug-resistance mdr1a/1b double knockout mice are more sensitive than wild type mice to acute arsenic toxicity, with higher arsenic accumulation in tissues. Toxicology 2002, 170(1-2):55-62.
12. Mandal B.K., Suzuki K.T. Arsenic round the world: a review. Talanta 2002, 58(1):201-235.
13. Marzolini C., Paus E., Buclin T., Kim R.B. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin. Pharmacol. Ther. 2004, 75(1):13-33.
14. Pavek P., Staud F., Fendrich Z., Sklenarova H., Libra A., Novotna M., Kopecky M., Nobilis M., Semecky V. Examination of the functional activity of P-glycoprotein in the rat placental barrier using rhodamine 123. J. Pharmacol. Exp. Ther. 2003, 305(3):1239-1250.
15. Sauna Z.E., Kimchi-Sarfaty C., Ambudkar S.V., Gottesman M.M. Silent polymorphisms speak: how they affect pharmacogenomics and the treatment of cancer. Cancer Res. 2007, 67(20):9609-9612.
16. Smit J.W., Huisman M.T., Van Tellingen O., Wiltshire H.R., Schinkel A.H. Absence or pharmacological blocking of placental P glycoprotein profoundly increases fetal drug exposure. J. Clin. Invest. 1999, 104:1441-1447.
17. Vahter M. Effects of arsenic on maternal and fetal health. Annu. Rev. Nutr. 2009, 29:381-399.
18. Xie Y., Liu J., Liu Y., Klaassen C.D., Waalkes M.P. Toxicokinetic and genomic analysis of chronic arsenic exposure in multidrug-resistance mdr1a/1b(-/-) double knockout mice. Mol. Cell Biochem. 2004, 255(1-2):11-18.
19. Xing Q., Gao R., Li H., Feng G., Xu M., Duan S., Meng J., Zhang A., Qin S., He L. Polymorphisms of the ABCB1 gene are associated with the therapeutic response to risperidone in Chinese schizophrenia patients. Pharmacogenomics 2006, 7(7):987-993.